Example ImageÃÀ¸ß÷

EN
EN
  • ÓªÒµ×Éѯ

    Öйú£º

    Email: marketing@medicilon.com.cn

    ÓªÒµ×ÉѯרÏߣº400-780-8018

    £¨½öÏÞЧÀÍ×Éѯ£¬£¬£¬£¬ÆäËûÊÂÒËÇ벦´ò´¨É³×ܲ¿µç»°£©

    ´¨É³×ܲ¿µç»°: +86 (21) 5859-1500

    ÍâÑó£º

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com

ÔÚÏßÁôÑÔ¡Á
µã»÷Çл»
Customer Center
¿Í»§ÖÐÐÄ

ÂÌÒ¶ÖÆÒ©Ç£ÊÖ¶÷»ªÒ©Òµ¡¢Ê¢ÒâÇé ÍÆ½ø¿¹ÒÖÓôÁ¢ÒìÒ©ÈôÐÀÁÖÉÌÒµ»¯Ø­¡°ÃÀ¡±ÌìÐÂÒ©ÊÂ

2022-12-02
|
»á¼ûÁ¿£º

¸±±¾_ÍøÕ¾ËõÂÔͼ__2022-12-02+17_10_13.jpeg

Ò½ÏßÒ©ÎÅ

1¡¢12ÔÂ1ÈÕ£¬£¬£¬£¬ÔÙ¶¦Ò½Ò©ÓëÆäÏàÖúͬ°éEntasis TherapeuticsµÄĸ¹«Ë¾InnovivaÐû²¼£¬£¬£¬£¬ÃÀ¹úFDAÒÑÊÜÀídurlobactam£¨SUL-DUR£©ÐÂÒ©ÉÏÊÐÉêÇ루NDA£©£¬£¬£¬£¬²¢ÊÚÓèÆäÓÅÏÈÉóÆÀ×ʸñ¡£¡£¡£¡£¡£¡£SUL-DURÊÇÒ»¿î¿¹ÉúËØ×éºÏÁÆ·¨£¬£¬£¬£¬ÓÃÓÚÖÎÁưüÀ¨¶àÖØÄÍÒ©ºÍ̼ÇàùϩÀàÄÍÒ©¾úÖêÔÚÄڵı«Âü²»¶¯¸Ë¾ú-´×Ëá¸Æ¸´ºÏÎïÒýÆðµÄѬȾ£¬£¬£¬£¬ÔÙ¶¦Ò½Ò©ÓµÓиÃÒ©ÔÚÑÇÌ«µØÇøµÄ¿ª·¢ºÍÉÌÒµ»¯¶À¼ÒȨÁ¦¡£¡£¡£¡£¡£¡£
2¡¢12ÔÂ1ÈÕ£¬£¬£¬£¬°²½ø£¨Amgen£©Ðû²¼ÁËÆäÔÚÑзÊÅÖÁÆ·¨AMG 133µÄ×îÐÂ1ÆÚÁÙ´²ÊÔÑéÊý¾Ý¡£¡£¡£¡£¡£¡£¹ûÈ»×ÊÁÏÏÔʾ£¬£¬£¬£¬AMG 133ÊÇÒ»¿îDZÔÚ¡°first-in-class¡±µÄ¿¹Ìå¶àëÄżÁªÒ©Î£¬£¬£¬Ã¿¸öÔÂÓÃÒ©Ò»´Î¡£¡£¡£¡£¡£¡£1ÆÚÁÙ´²ÊÔÑéЧ¹ûÏÔʾ£¬£¬£¬£¬ÊÜÊÔÕß¾­×î¸ß¼ÁÁ¿AMG 133ÖÎÁÆ12ÖܺóÌåÖØïÔÌ­ÁË14.5%¡£¡£¡£¡£¡£¡£
3¡¢12ÔÂ1ÈÕ£¬£¬£¬£¬¿ªÍØÒ©ÒµÐû²¼£¬£¬£¬£¬Æä×ÔÖ÷Ñз¢¡¢Ç±ÔÚͬÀàÊ×´´µÄ¸£ÈðËû¶÷£¨KX-826£©ÖÎÁƳÉÄêÅ®ÐÔÐÛ¼¤ËØÐÔÍÑ·¢£¨AGA£©µÄÖйúIIÆÚÁÙ´²ÊÔÑéÖ÷ҪЧ¹û¡£¡£¡£¡£¡£¡£Ñо¿Åú×¢£¬£¬£¬£¬¸£ÈðËû¶÷µÄÁÆÐ§¾ßÓÐÁÙ´²ÒâÒ壬£¬£¬£¬ÔÚÔö½øÃ«±¬·¢³¤ÉÏ£¨Í¨¹ýÄ¿µÄÇøÓòÄÚ·Çë¥Ã«Êý(TAHC)Ȩºâ£©ÏÔʾ³öÏÔÖøµÄͳ¼ÆÑ§²î±ð£¬£¬£¬£¬ÇÒÇå¾²ÐÔÓÅÒì¡£¡£¡£¡£¡£¡£

ͶÈÚÒ©ÊÂ

1¡¢12ÔÂ1ÈÕ£¬£¬£¬£¬ÂÌÒ¶ÖÆÒ©Ð¯ÊÖ¶÷»ªÒ©Òµ¡¢Ê¢ÒâÇ鿵½¡¹¤Òµ¼¯Íż°ÆäÆìϱ±¾©Ê¢ÒâÇ黥ÁªÍøÒ½ÔºÓÐÏÞ¹«Ë¾£¬£¬£¬£¬¾ÍÆä½üÆÚ»ñÅúÉÏÊеÄÖØ°õ¿¹ÒÖÓôÁ¢ÒìÒ©ÈôÐÀÁÖ?£¨ÑÎËáÍгµØÎÄÀ­·¨ÐÁ»ºÊÍÆ¬£©£¬£¬£¬£¬ÅäºÏÇ©ÊðÈý·½Õ½ÂÔÏàÖúЭÒé¡£¡£¡£¡£¡£¡£×ÊÁÏÏÔʾ£¬£¬£¬£¬ÈôÐÀÁÖ?ÊÇÖйúÊ׸ö×ÔÖ÷Ñз¢²¢ÓµÓÐ×ÔÖ÷֪ʶ²úȨÓÃÓÚÖÎÁÆÒÖÓôÖ¢µÄ»¯Ò©1ÀàÁ¢ÒìÒ©¡£¡£¡£¡£¡£¡£

¿Æ¼¼Ò©ÑÐ

1¡¢¿ËÈÕ£¬£¬£¬£¬¹ú¼ÊÔÓÖ¾Cancer ResearchÉÏ£¬£¬£¬£¬À´×ÔÄϰ²ÆÕ¶Ù´óѧµÈ»ú¹¹µÄ¿ÆÑ§¼ÒÃÇͨ¹ýÑо¿ÉîÈëÃ÷È·ÁËijЩ°©Ö¢¶Ô»úÌåÃâÒßÁÆ·¨Ã»Óз´Ó¦µÄÔµ¹ÊÔ­ÓÉ£¬£¬£¬£¬Í¬Ê±Ïà¹ØÑо¿Ð§¹û»òÓÐÍû×ÊÖúÖÎÁƸü¶à°©Ö¢»¼Õß[1]¡£¡£¡£¡£¡£¡£

[1] Massimiliano Mellone,Klaudia Piotrowska,Giulia Venturi£¬£¬£¬£¬et al. ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy Resistance, Cancer Research (2022). DOI: 10.1158/0008-5472.CAN-22-0435

¹Ø×¢¡°ÃÀ¸ß÷Medicilon¡±¹«Öںţ¬£¬£¬£¬¶©ÔÄÀ¸Ä¿»ñÈ¡ÌìÌìÒ½Ò©×ÊѶ-1.png

Ïà¹ØÐÂÎÅ
¡Á
ËÑË÷ÑéÖ¤
µã»÷Çл»
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿